C. Bovet

Type de document

Articles (6) Recensions (2)

Co-auteur

Date

Source

Mot-clé

Patients (6) Patients (6) laboratoire (5) Ci (Chinese poetry) (5) surveillance (4) analyse (4) Monitoring (4) Area (4) Area (4) Performance (4) Mass spectrometry (4) Performance (4) plasma (4) Practice (3) temps (durée) (2) norme (2) association (2) Case (2) Inhibitors (2) Time (2) Social groups (2) Human beings (2) Heparin (2) Grammar, Comparative and general--Case (2) Confidence (2) Case (2) Addition (2) Use (2) puits (1) thérapie (1)

Documents écrit par C. Bovet (6) | parle de C. Bovet (0)

Determination of Anti-Xa Inhibitor Plasma Concentrations Using a Universal Edoxaban Calibrator.
A. Burger et al. (20 juin 2023)
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
E. Schmulenson et al.
Prothrombinase-Induced Clotting Time to Measure Drug Concentrations of Rivaroxaban, Apixaban, and Edoxaban in Clinical Practice: A Cross-Sectional Study.
V. Sathanantham et al. (11 juil. 2022)
Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study.
T. Meihandoest et al. (2022)
A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation.
G. Willekens et al.
Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements.
T. Meihandoest et al. (2021)